In the Claims

 (Currently amended) A pharmaceutical composition comprising at least one a first therapeutic agent selected from the group consisting of:

azo-bonded 4-APAA compound; non-azo bonded 4-APAA compound;

azo-bonded 5-ASA compound;

non-azo bonded 5-ASA compound: and

at least one a second therapeutic agent comprising a selected from the group consisting of:

4-APAA compound azo bonded to a 5-ASA compound; and a combination of 4-APAA compound and a 5-ASA compound.

- (Previously presented) The pharmaceutical composition of claim 1 further comprising another
 therapeutic agent selected from the group consisting of: steroids, antibiotics, stool softeners, stool
 hardeners, nutraceuticals, probiotic agents and organisms, and nicotinic agents.
- (Currently amended) The pharmaceutical composition of claim 1 formulated to deliver the <u>first</u> therapeutic agents-to the small intestine and/or the celon.
- (Currently amended) The pharmaceutical composition of claim 1 formulated to release the <u>first</u> therapeutic agents along the length of the small intestine and <u>the second therapeutic agent along the length</u> of colon.
- (Currently amended) The pharmaceutical composition of claim 1 formulated to release the second
 therapeutic agents along the length of the distal portion of the small intestine and the colon.
- (Currently amended) The pharmaceutical composition of claim 1 formulated to release the second therapeutic agents along the length of the colon.
- (Original) The pharmaceutical composition of claim 1 formulated to pass through the stomach
 and to release the active agent in the intestine.
- (Currently amended) The pharmaceutical composition of claim 6 1 formulated as a suppository.

(Currently amended) The pharmaceutical composition of claim 6 1 formulated for administration
as an enema.

10-14. (Cancelled)

15. (Currently amended) A pharmaceutical composition comprising at least two therapeutic agents selected from the group consisting of:

azo-bonded 4 APAA compound;
non-azo-bonded 4 APAA compound;
azo-bonded 5 ASA compound;
non-azo-bonded 5 ASA compound;
4 APAA compound azo-bonded to a 5 ASA compound; and
a combination of 4 APAA compound and a 5 ASA compound.

a first and second therapeutic agent, wherein the first therapeutic agent composition is formulated to release in the stomach or small intestine and selected from the group consisting of

azo-bonded 4-APAA compound; non-azo bonded 4-APAA compound; azo-bonded 5-ASA compound; and non-azo bonded 5-ASA compound; and

wherein the second therapeutic agent is formulated to release in the distal portion of the small intestine or colon and selected from the group consisting of:

4-APAA compound azo bonded to a 5-ASA compound; and a combination of 4-APAA compound and a 5-ASA compound.

(a) at least one component selected from the group consisting of a first and a second component, wherein the first component comprising one or more of the therapeutic agents formulated for release in the stomach, and the second component comprising one or more of the therapeutic agents formulated for release in the small intestine or distal portion of the small intestine, wherein the therapeutic agents for the distal portion of the small intestine is a 4 APAA compound azo bonded to a 5 ASA compound or a combination of 4 APAA and 5 ASA compounds;

and

— (b) a third component comprising one or more of the therapeutic agents formulated for release in the colon-

16.-29. (Cancelled)

30. (Currently amended) A method of treating an inflammatory colon condition comprising administering to a subject a pharmaceutical composition of claim 1 or 15, 2-, 3, 4, 5, 6, 7, 8, 9, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 32 in an amount sufficient to reduce the inflammatory gastrointestinal condition.

31.-32. (Cancelled).

33. (New) The pharmaceutical composition of claim 15 wherein:

the first therapeutic agent is a 5-ASA compound formulated for release in the stomach and the second therapeutic agent is a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine.

34. (New) The pharmaceutical composition of claim 15 wherein:

the first therapeutic agent is a 4-APAA compound formulated for release in the stomach and the second therapeutic agent is a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine.

35. (New) The pharmaceutical composition of claim 15 wherein:

the first therapeutic agent is a 5-ASA compound formulated for release in the small intestine and the second therapeutic agent is a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine.

36. (New) The pharmaceutical composition of claim 15 wherein:

the first therapeutic agent is a 4-APAA compound formulated for release in the small intestine and the second therapeutic agent is a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine.

37. (New) The pharmaceutical composition of claim 15 wherein:

the first therapeutic agent is a 5-ASA compound formulated for release in the stomach and the second therapeutic agent is a 5-ASA compound and a 4-APAA compound formulated for release in the colon.

38. (New) The pharmaceutical composition of claim 15 wherein:

the first therapeutic agent is a 4-APAA compound formulated for release in the stomach and the second therapeutic agent is a 5-ASA compound and a 4-APAA compound formulated for release in the colon.

39. (New) The pharmaceutical composition of claim 15 wherein:

the first therapeutic agent is a 5-ASA compound formulated for release in the small intestine and the second therapeutic agent is a 5-ASA compound and a 4-APAA compound formulated for release in the colon.

40. (New) The pharmaceutical composition of claim 15 wherein:

the first therapeutic agent is a 4-APAA compound formulated for release in the small intestine and the second therapeutic agent is a 5-ASA compound and a 4-APAA compound formulated for release in the colon.